[{"id":"10f316f1-d64e-4655-beaa-fef075e7fae2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03188991","created_at":"2021-01-18T15:43:26.308Z","updated_at":"2024-07-02T16:36:29.131Z","phase":"Phase 2","brief_title":"Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms","source_id_and_acronym":"NCT03188991","lead_sponsor":"NanOlogy, LLC","biomarkers":" KRAS • CEACAM5","pipe":"","alterations":" ","tags":["KRAS • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NanoPac (paclitaxel nanoformulation)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/29/2017","start_date":" 09/29/2017","primary_txt":" Primary completion: 06/29/2020","primary_completion_date":" 06/29/2020","study_txt":" Completion: 06/29/2020","study_completion_date":" 06/29/2020","last_update_posted":"2021-06-14"}]